Sulphonamide inhibition profile of Staphylococcus aureus β-carbonic anhydrase.
Linda J UrbanskiSilvia BuaAndrea AgeliMarianne KuuslahtiVesa P HytönenClaudiu T SupuranSeppo ParkkilaPublished in: Journal of enzyme inhibition and medicinal chemistry (2021)
This paper presents the production and kinetic and inhibitory characterisation of β-carbonic anhydrase from the opportunistic bacterium Staphylococcus aureus (SauBCA). From the eight different carbonic anhydrase (CA) families known to date, humans have only the α-form, whereas many clinically relevant pathogens have β- and/or γ-form(s). Based on this discovery, β- and γ-CAs have been introduced as promising new anti-infective targets. The results of this study revealed that recombinant SauBCA possesses significant CO2 hydration activity with a kcat of 1.46 × 105 s-1 and a kcat/KM of 2.56 × 107 s- 1M-1. Its enzymatic function was inhibited by various sulphonamides in the nanomolar - micromolar range, and the Ki of acetazolamide was 628 nM. The best inhibitor was the clinically used sulfamide agent famotidine (Ki of 71 nM). The least efficient inhibitors were zonisamide and dorzolamide. Our work encourages further investigations of SauBCA in an attempt to discover novel drugs against staphylococcal infections.
Keyphrases
- staphylococcus aureus
- biofilm formation
- photodynamic therapy
- methicillin resistant staphylococcus aureus
- small molecule
- neoadjuvant chemotherapy
- crispr cas
- hydrogen peroxide
- high throughput
- squamous cell carcinoma
- single cell
- antimicrobial resistance
- escherichia coli
- protein kinase
- gram negative
- multidrug resistant
- rectal cancer
- lymph node
- cell free
- locally advanced